(a), Expression of TGFβ1 and ALK5 in HUVECs treated with BMP9 as shown by real-time PCR, immunoblotting and immunostaining.
(b) Activation of pSMAD2 in HUVECs treated with BMP9 as shown by immunoblotting and immunostaining.
(c-d) Expression of HOXD3, TGFβ1 and ALK5 in HUVECs after infection with lentiviral vectors over-expressing HOXD3, as shown by real-time PCR, immunoblotting and immunostaining.
(e) Activation of pSMAD2 in HUVECs after infection with lentiviral vectors over-expressing HOXD3, as shown by immunoblotting and immunostaining.
(f) HOXD3 DNA-binding sites (HS) in the promoter of the Tgfβ1 gene.
(g) Increased HOXD3 DNA-binding in the Tgfβ1 promoter in Mgp−/− aortas as shown by ChIP-assays.
Data were analyzed by Student’s t test. ***, P<0.001. Error bars are standard deviation. ***, P < 0.001. Scale bar, 50 μm.